AIMS: While suboptimal adherence to statin medication has been quantified in real-world patient settings, a better understanding of its impact is needed, particularly with respect to distinct problems of medication taking. Our aim was to synthesize current evidence on the impacts of statin adherence, discontinuation and persistence on cardiovascular disease and mortality outcomes. METHODS: We conducted a systematic review of peer-reviewed studies using a mapped search of Medline, Embase and International Pharmaceutical Abstracts databases. Observational studies that met the following criteria were included: defined patient population;statin adherence exposure; defined study outcome [i.e. cardiovascular disease (CVD), mortality]; and reporting of statin-specific results. RESULTS: Overall, 28 studies were included, with 19 studies evaluating outcomes associated with statin adherence, six with statin discontinuation and three with statin persistence. Among adherence studies, the proportion of days covered was the most widely used measure, with the majority of studies reporting increased risk of CVD (statistically significant risk estimates ranging from 1.22 to 5.26)and mortality (statistically significant risk estimates ranging from 1.25 to 2.54) among non-adherent individuals. There was greater methodological variability in discontinuation and persistence studies. However, findings of increased CVD (statistically significant risk estimates ranging from 1.22 to 1.67) and mortality (statistically significant risk estimates ranging from 1.79 to 5.00) among nonpersistent individuals were also consistently reported. CONCLUSIONS: Observational studies consistently report an increased risk of adverse outcomes associated with poor statin adherence. These findings have important implications for patients and physicians and emphasize the importance of monitoring and encouraging adherence to statin therapy.
AIMS: While suboptimal adherence to statin medication has been quantified in real-world patient settings, a better understanding of its impact is needed, particularly with respect to distinct problems of medication taking. Our aim was to synthesize current evidence on the impacts of statin adherence, discontinuation and persistence on cardiovascular disease and mortality outcomes. METHODS: We conducted a systematic review of peer-reviewed studies using a mapped search of Medline, Embase and International Pharmaceutical Abstracts databases. Observational studies that met the following criteria were included: defined patient population;statin adherence exposure; defined study outcome [i.e. cardiovascular disease (CVD), mortality]; and reporting of statin-specific results. RESULTS: Overall, 28 studies were included, with 19 studies evaluating outcomes associated with statin adherence, six with statin discontinuation and three with statin persistence. Among adherence studies, the proportion of days covered was the most widely used measure, with the majority of studies reporting increased risk of CVD (statistically significant risk estimates ranging from 1.22 to 5.26)and mortality (statistically significant risk estimates ranging from 1.25 to 2.54) among non-adherent individuals. There was greater methodological variability in discontinuation and persistence studies. However, findings of increased CVD (statistically significant risk estimates ranging from 1.22 to 1.67) and mortality (statistically significant risk estimates ranging from 1.79 to 5.00) among nonpersistent individuals were also consistently reported. CONCLUSIONS: Observational studies consistently report an increased risk of adverse outcomes associated with poor statin adherence. These findings have important implications for patients and physicians and emphasize the importance of monitoring and encouraging adherence to statin therapy.
Authors: Jari Haukka; Leo Niskanen; Timo Partonen; Jouko Lönnqvist; Jari Tiihonen Journal: Pharmacoepidemiol Drug Saf Date: 2011-09-29 Impact factor: 2.890
Authors: Mary A De Vera; Hyon Choi; Michal Abrahamowicz; Jacek Kopec; Maria Victoria Goycochea-Robles; Diane Lacaille Journal: Ann Rheum Dis Date: 2011-03-06 Impact factor: 19.103
Authors: Mary A De Vera; Hyon Choi; Michal Abrahamowicz; Jacek Kopec; Diane Lacaille Journal: Arthritis Care Res (Hoboken) Date: 2012-03-29 Impact factor: 4.794
Authors: Philippe Tuppin; Anke Neumann; Nicolas Danchin; Christine de Peretti; Alain Weill; Philippe Ricordeau; Hubert Allemand Journal: Arch Cardiovasc Dis Date: 2010-07-22 Impact factor: 2.340
Authors: Stella S Daskalopoulou; Joseph A C Delaney; Kristian B Filion; James M Brophy; Nancy E Mayo; Samy Suissa Journal: Eur Heart J Date: 2008-07-29 Impact factor: 29.983
Authors: Alice Dragomir; Robert Côté; Michel White; Lyne Lalonde; Lucie Blais; Anick Bérard; Sylvie Perreault Journal: Value Health Date: 2009-08-20 Impact factor: 5.725
Authors: Veit Sandfort; David A Bluemke; Jose Vargas; Jeffrey A Brinker; Gary Gerstenblith; Thomas Kickler; Gang Zheng; Ji Li; Shaoguang Chen; Hong Lai; Elliot K Fishman; Shenghan Lai Journal: J Addict Med Date: 2017 Mar/Apr Impact factor: 3.702
Authors: Emily Herrett; Elizabeth Williamson; Kieran Brack; Alexander Perkins; Andrew Thayne; Haleema Shakur-Still; Ian Roberts; Danielle Prowse; Danielle Beaumont; Zahra Jamal; Ben Goldacre; Tjeerd van Staa; Thomas M MacDonald; Jane Armitage; Michael Moore; Maurice Hoffman; Liam Smeeth Journal: Health Technol Assess Date: 2021-03 Impact factor: 4.014
Authors: Kamlesh Khunti; Mark D Danese; Lucie Kutikova; David Catterick; Francisco Sorio-Vilela; Michelle Gleeson; Sreenivasa Rao Kondapally Seshasai; Jack Brownrigg; Kausik K Ray Journal: JAMA Netw Open Date: 2018-12-07